

Datasheet for ABIN5668216

Recombinant anti-CD22 (Epratuzumab Biosimilar) antibody



[Go to Product page](#)

Overview

Quantity:	200 µg
Target:	CD22 (Epratuzumab Biosimilar)
Reactivity:	Cynomolgus, Human, Rhesus Monkey
Host:	Human
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
Application:	Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)

Product Details

Purpose:	Anti-CD22 [hL22 (Epratuzumab)], Human IgG1, kappa
Immunogen:	This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
Clone:	HL22
Isotype:	IgG1 kappa
Specificity:	This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
Cross-Reactivity:	Cynomolgus, Rhesus Monkey

Product Details

Characteristics:	Original Species of Ab: Human Original Format of Ab: IgG1
Purification:	Protein A affinity purified
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method

Target Details

Target:	CD22 (Epratuzumab Biosimilar)
Abstract:	CD22 (Epratuzumab Biosimilar) Products
Target Type:	Biosimilar
Background:	Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
UniProt:	P20273

Application Details

Application Notes:	Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
Restrictions:	For Research Use only

Handling

Concentration:	1 mg/mL
Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling

Storage:	4 °C,-20 °C
----------	-------------

Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
------------------	--